Type of information: Clinical research agreement
Compound: VXM01 and avelumab (MSB0010718C)
Company: Vaximm (Germany) Merck KGaA (Germany) Pfizer (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
- immunotherapy product/therapeutic vaccine/monoclonal antibody/immune checkpoint inhibitor. VXM01 is designed to stimulate the patients’ own immune system to destroy tumor-associated blood vessels, which are essential for tumors growth. VXM01 is given orally and acts in the gut to induce an anti-tumor response of the immune system.
- Avelumab is a fully human IgG1 monoclonal antibody that binds to the PD-L1 (programmed death-ligand 1) protein, which is present at high levels in many cancer types. By competitively blocking the interaction with PD-1 receptors, it is believed that avelumab thereby restores anti-tumor T-cell responses and inhibits tumor growth. Pfizer and Merck KGaA are jointly developing avelumab currently in development by Merck KGaA as a potential treatment for multiple types of cancer.
Disease: colorectal cancer, glioblastoma
- • On May 9, 2017, Vaxxim announced that it has entered into a collaboration agreement with Merck KGaA and Pfizer to evaluate avelumab in combination with VXM01. Under the terms of the agreement, Vaximm will be responsible for conducting two open-label Phase I/II trials - one in glioblastoma and one in metastatic colorectal cancer.